MELISSA SHARP: Open Payments
NPI 1336837210 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,216 in 34 payments from 14 companies in 2025. Trend: 2023 $13 · 2024 $1,069 · 2025 $1,216
Food & beverage: $1,216
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $255 |
| ABBVIE INC. | 7 | $193 |
| Janssen Pharmaceuticals, Inc | 2 | $152 |
| Otsuka America Pharmaceutical, Inc. | 3 | $144 |
| Vanda Pharmaceuticals Inc. | 2 | $128 |
| Alkermes, Inc. | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Bausch Health US, LLC | 1 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
Products named: CAPLYTA, VRAYLAR, SPRAVATO, REXULTI, FANAPT, ARISTADA, UZEDY, APLENZIN.
Industry payments across VA — which companies pay providers there.
